The ct-qPCR Test (unapproved for diagnostics) and its administrative procedures are not only flawed (problems with adequate swab) but are a non-specific, catch all test which is known for giving false positives for flu-like viruses as well as many others.
These tests do not give adequate clues about the amount of viral infection (slight or severe) and whether or not the virus is alive since it examines elements of RNA debris, not the entire genetic sequence. Detection of a dead virus has no clinical meaning as they are present in any respiratory disease unrelated to the disease itself.
Clinically and epidemiologically PCR test "positives" or test "negatives" are useless and can be outright misleading, giving false information about virus spreading dynamics as well as create artifacts of clinical cases of COVID that are not there.
The PCR test "positive" does not necessarily imply disease even if the presence of the virus is confirmed by full sequencing, also the PCR’s RNA fragments do not definitively make a clinical case for COVID attribution.
"Negative" tests for respiratory symptomatic patients are also problematic as they give no clue to physicians about possible diagnosis of other possibly present respiratory diseases.
PCR tests, put simply, are a diagnostic fraud, a fact indirectly admitted by the FDA.
The FDA warned about the high likelihood of false positive test results in emergency approval letters to manufacturers of “COVID” testing kits which inherently fail to assure adequate SC2 specificity.
The FDA announced on May 4th that companies selling "Covid" PCR antibody tests must submit data proving accuracy within the next 10 days or face removal from the market.
On May 4th the FDA stated openly, "a concerning number of commercial serology tests are being promoted inappropriately, including for diagnostic use, or are performing poorly based on an independent evaluation" conducted by the National Institutes of Health.
The antibody tests are an effort to detect whether a person had been infected with the coronavirus, but results have been widely varied. Since mid-March, the agency permitted dozens of manufacturers to sell the tests without providing evidence that they are accurate.
The F.D.A.’s action follows a report by more than 50 scientists, which found that only three out of 14 antibody tests gave consistently reliable results, and even the best had flaws. An evaluation by the National Institutes of Health, working with other federal health agencies, also found “a concerning number” of commercial tests that are performing poorly, the F.D.A. said.
The results from these flawed tests, tests that had been rushed to market, were not only repeated as gospel by media throughout the country but were and are being used as (mis)information to guide public policy.
In these tests the SC2 virus was NOT isolated from samples of clinical cases casually attributed to COVID phenology but "supposedly" associated with COVID, as many other biological agents and pathogens are also found to be associated with COVID clinical cases.
Such recklessly vague, catch-all clinical descriptions of COVID covers a broad spectrum of existing diseases or conditions. This can be directly responsible for injurious or deadly therapies, including invasive ventilation known to kill up to 80% of COVID patients in some areas, as well as blatantly wrong protocols and drug regimes doctors are still compelled to follow.
Serological tests for SC2 antibody are much more reliable and in fact can diagnose ongoing infection by detection of short term antibodies within a few days of viral inoculation as well as longer term exposure antibodies within a span of two weeks or more when SC2 is removed from organism or it is still present but dead and unable to infect human cells.
Note for example:
Manufacturer Creative Diagnostics website- SARS-CoV-2 Coronavirus Multiplex RT-qPCR Kit (CD019RT)
Regulatory status: For research use only, NOT FOR USE IN DIAGNOSTICS PROCEDURES.
Specificity: non-specific interference of Influenza A Virus (H1N1), Influenza B Virus (Yamagata), Respiratory Syncytial Virus (type B), Respiratory Adenovirus (type 3, type 7), Parainfluenza Virus (type 2), Mycoplasma Pneumoniae, Chlamydia Pneumoniae, etc.,.
From FDA approval letter for Bio-Rad Laboratories, Inc., RTqPCR test.
Positive results are indicative of the presence of SARS-CoV-2 nucleic acid; clinical correlation with patient history and other diagnostic information is necessary to determine patient infection status. Positive results DO NOT rule out bacterial infection or co-infection with other viruses.
Compare to here:
Serological test kit approval letter for the same manufacturer:
Your product is a qualitative test for the detection of total antibodies (including IgM/IgA/IgG) against SARS-CoV-2 in serum and plasma (EDTA). The product is intended for use as an aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Note that there is no questioning of positive serological results or warning about impact of co-infection.
C19 is decidedly not some alien, unique virus- it is a SC2 virus (that was fully sequenced) out of at least a hundred others present within our respiratory system. Nobody cares to pay attention to these others as the immune system in a healthy person deals with them, just as a healthy immune system does with SC2, influenza and other viral contagions.
What we are dealing with is not the result of some unique deadly virus rather it is the result of the collapsed health of populations due to extreme social stresses, rapidly deteriorating environmental conditions and the devastation of public health institutions worldwide which has produced hundreds of millions of people sick and dying from preventable diseases every year.